Biosyntech to Initiate European Clinical Trials for BST-GEL.Business Editors QUEBEC--(BUSINESS WIRE)--Oct. 11, 2000 BIOSYNTECH (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BSYI) BIOSYNTECH Inc. (OTCBB:BSYI) today announced it has initiated clinical trials for one of its BST-GEL(TM) products. The clinical trials will be conducted at four European centres in both France and Belgium. The product under study is a BST-GEL implant to be used in cosmetic surgery cosmetic surgery, plastic surgery for cosmetic purposes, such as the improvement of the appearance of the face by removing wrinkles or reshaping the nose. and in facial soft tissue augmentation. "BST-GEL's properties make it an ideal facial implant," said Marie Claire Marie Claire is a monthly woman’s magazine conceived in France but also distributed in other countries with editions specific to them and in their languages. While each country shares its own special voice with its audience, the United States edition focuses on women Pilon, BIOSYNTECH Chief Executive Officer. "Natural in terms of appearance and texture, it is also estimated that the BST-GEL facial implant will have a substantially longer duration than currently marketed products for this indication." BIOSYNTECH injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. implants and solutions are classified as medical devices whose regulatory approval process is shorter than the regulatory approval process for medications. BIOSYNTECH indicated that following completion of the trials, the company will seek approval of its BST-GEL facial implant from European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community regulatory authorities. "We would anticipate E.U. approval for the use of this innovative product for both indications in approximately one year," added Ms Pilon. Additionally, clinical trials on other BST-GEL products are expected to begin shortly. BIOSYNTECH is an advanced biomaterials company specialising in tissue engineering, the delivery of advanced injectable biomaterials and biotherapeutic agents. This press release contains certain "forward-looking" statements, as defined in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in the company's filings with the regulatory authorities having jurisdiction. No regulatory authority has approved or disapproved the content of this release. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion